EY Case Highlights Problem with ‘Integrity Lite’
Category: Governance & Compliance
First Amendment Claims Seen as Rx for Drug Makers, Headache for Consumers
Decisions in recent legal cases are fueling debate about whether the First Amendment’s protection of commercial speech could undermine the FDA’s ability to prevent drug marketing abuses.
